Clarity have finalised clinical trial of diagnostic product SARTATE™
Clarity Pharmaceuticals have finalised their cutting edge clinical trial of the lead diagnostic product MeCOSar-octreotate (SARTATE™) in collaboration with key opinion leaders at the University of Melbourne and the Peter MacCallum Cancer Centre. The trial, led by Prof Rodney Hicks, a world renowned clinician at the Peter MacCallum Cancer Centre, has been highly successful based on the information to date. Results of the trial will be presented at the SNMMI global conference in June 2016.
This is an exceptional milestone for Clarity as it strengthens their unique expertise in conducting clinical Phase 0 services and enhances the ability to characterise and de-risk biological molecules by imaging in humans before conducting Phase 1 therapeutic studies. Clarity’s technology can increase the likelihood of clinical response by leveraging personalised medicine approach and thus reduce trial size, budget and timelines, making trials shorter, cheaper and faster to market.
Clarity is pleased to have recently received an Australian government grant of $1m to extend this product to conduct a state-of-the-art Phase 2a efficacy trial using Cu-64/Cu-67 theranostic pairing.
Clarity is a client of ATP Innovations, Australia’s leading business incubator.
Follow Clarity Pharmaceuticals for more great news.